Wuqiang Zhu1, Meng Zhao1, Saidulu Mattapally1, Sifeng Chen1, Jianyi Zhang2. 1. From the Department of Biomedical Engineering, School of Medicine, School of Engineering, University of Alabama at Birmingham (W.Z., M.Z., S.M., J.Z.); and Department of Physiology and Pathophysiology, Fudan University, Shanghai, China (M.Z., S.C.). 2. From the Department of Biomedical Engineering, School of Medicine, School of Engineering, University of Alabama at Birmingham (W.Z., M.Z., S.M., J.Z.); and Department of Physiology and Pathophysiology, Fudan University, Shanghai, China (M.Z., S.C.). jayzhang@uab.edu.
Abstract
RATIONALE: The effectiveness of transplanted, human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) for treatment of ischemic myocardial injury is limited by the exceptionally low engraftment rate. OBJECTIVE: To determine whether overexpression of the cell cycle activator CCND2 (cyclin D2) in hiPSC-CMs can increase the graft size and improve myocardial recovery in a mouse model of myocardial infarction by increasing the proliferation of grafted cells. METHODS AND RESULTS: Human CCND2 was delivered to hiPSCs via lentiviral-mediated gene transfection. In cultured cells, markers for cell cycle activation and proliferation were ≈3- to 7-folds higher in CCND2-overexpressing hiPSC-CMs (hiPSC-CCND2OECMs) than in hiPSC-CMs with normal levels of CCND2 (hiPSC-CCND2WTCMs; P<0.01). The pluripotent genes (Oct 4, Sox2, and Nanog) decrease to minimal levels and undetectable levels at day 1 and 10 after differentiating to CMs. In the mouse myocardial infarction model, cardiac function, infarct size, and the number of engrafted cells were similar at week 1 after treatment with hiPSC-CCND2OECMs or hiPSC-CCND2WTCMs but was about tripled in hiPSC-CCND2OECM-treated than in hiPSC-CCND2WTCM-treated animals at week 4 (P<0.01). The cardiac function and infarct size were significantly better in both cell treatment groups' hearts than in control hearts, which was most prominent in hiPSC-CCND2OECM-treated animals (P<0.05, each). No tumor formation was observed in any hearts. CONCLUSIONS: CCND2 overexpression activates cell cycle progression in hiPSC-CMs that results in a significant enhanced potency for myocardial repair as evidenced by remuscularization of injured myocardium. This left ventricular muscle regeneration and increased angiogenesis in border zone are accompanied by a significant improvement of left ventricular chamber function.
RATIONALE: The effectiveness of transplanted, human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) for treatment of ischemic myocardial injury is limited by the exceptionally low engraftment rate. OBJECTIVE: To determine whether overexpression of the cell cycle activator CCND2 (cyclin D2) in hiPSC-CMs can increase the graft size and improve myocardial recovery in a mouse model of myocardial infarction by increasing the proliferation of grafted cells. METHODS AND RESULTS:HumanCCND2 was delivered to hiPSCs via lentiviral-mediated gene transfection. In cultured cells, markers for cell cycle activation and proliferation were ≈3- to 7-folds higher in CCND2-overexpressing hiPSC-CMs (hiPSC-CCND2OECMs) than in hiPSC-CMs with normal levels of CCND2 (hiPSC-CCND2WTCMs; P<0.01). The pluripotent genes (Oct 4, Sox2, and Nanog) decrease to minimal levels and undetectable levels at day 1 and 10 after differentiating to CMs. In the mousemyocardial infarction model, cardiac function, infarct size, and the number of engrafted cells were similar at week 1 after treatment with hiPSC-CCND2OECMs or hiPSC-CCND2WTCMs but was about tripled in hiPSC-CCND2OECM-treated than in hiPSC-CCND2WTCM-treated animals at week 4 (P<0.01). The cardiac function and infarct size were significantly better in both cell treatment groups' hearts than in control hearts, which was most prominent in hiPSC-CCND2OECM-treated animals (P<0.05, each). No tumor formation was observed in any hearts. CONCLUSIONS:CCND2 overexpression activates cell cycle progression in hiPSC-CMs that results in a significant enhanced potency for myocardial repair as evidenced by remuscularization of injured myocardium. This left ventricular muscle regeneration and increased angiogenesis in border zone are accompanied by a significant improvement of left ventricular chamber function.
Authors: Massimiliano Gnecchi; Huamei He; Olin D Liang; Luis G Melo; Fulvio Morello; Hui Mu; Nicolas Noiseux; Lunan Zhang; Richard E Pratt; Joanne S Ingwall; Victor J Dzau Journal: Nat Med Date: 2005-04 Impact factor: 53.440
Authors: Felix B Engel; Michael Schebesta; Mychelle T Duong; Gang Lu; Shuxun Ren; Jeffery B Madwed; Huiping Jiang; Yibin Wang; Mark T Keating Journal: Genes Dev Date: 2005-05-03 Impact factor: 11.361
Authors: Peter K Busk; Jirina Bartkova; Claes C Strøm; Linda Wulf-Andersen; Rebecca Hinrichsen; Tue E H Christoffersen; Lucia Latella; Jiri Bartek; Stig Haunsø; Søren P Sheikh Journal: Cardiovasc Res Date: 2002-10 Impact factor: 10.787
Authors: D A Taylor; B Z Atkins; P Hungspreugs; T R Jones; M C Reedy; K A Hutcheson; D D Glower; W E Kraus Journal: Nat Med Date: 1998-08 Impact factor: 53.440
Authors: Ke Wei; Vahid Serpooshan; Cecilia Hurtado; Marta Diez-Cuñado; Mingming Zhao; Sonomi Maruyama; Wenhong Zhu; Giovanni Fajardo; Michela Noseda; Kazuto Nakamura; Xueying Tian; Qiaozhen Liu; Andrew Wang; Yuka Matsuura; Paul Bushway; Wenqing Cai; Alex Savchenko; Morteza Mahmoudi; Michael D Schneider; Maurice J B van den Hoff; Manish J Butte; Phillip C Yang; Kenneth Walsh; Bin Zhou; Daniel Bernstein; Mark Mercola; Pilar Ruiz-Lozano Journal: Nature Date: 2015-09-16 Impact factor: 49.962
Authors: Xi Lou; Meng Zhao; Chengming Fan; Vladimir G Fast; Mani T Valarmathi; Wuqiang Zhu; Jianyi Zhang Journal: Cardiovasc Res Date: 2020-03-01 Impact factor: 10.787
Authors: Ke Huang; Emily W Ozpinar; Teng Su; Junnan Tang; Deliang Shen; Li Qiao; Shiqi Hu; Zhenhua Li; Hongxia Liang; Kyle Mathews; Valery Scharf; Donald O Freytes; Ke Cheng Journal: Sci Transl Med Date: 2020-04-08 Impact factor: 17.956